The Safety and Effectiveness of r-HuEPO in Patients With AIDS and Anemia Caused by AIDS and Treatment With AZT
Not Applicable
Completed
- Conditions
- HIV InfectionsCytopenias
- Registration Number
- NCT00002302
- Lead Sponsor
- Ortho Pharmaceuticals
- Brief Summary
To determine the safety and efficacy of erythropoietin administered subcutaneously to AIDS patients with anemia secondary to their disease and/or concomitant zidovudine (AZT) therapy. Efficacy will be assessed by correction of anemia and decrease in transfusion requirements.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie r-HuEPO's efficacy in correcting anemia in AIDS patients on AZT therapy?
How does r-HuEPO compare to standard blood transfusion protocols in managing AIDS-related anemia?
Are there specific biomarkers that predict response to r-HuEPO in HIV-infected individuals with AZT-induced anemia?
What adverse event profiles have been observed in r-HuEPO trials for HIV-related anemia and how are they managed?
What are the current combination therapies involving r-HuEPO for treating anemia in HIV patients undergoing antiretroviral treatment?
Trial Locations
- Locations (2)
AIDS Research Consortium of Atlanta
🇺🇸Atlanta, Georgia, United States
Ortho Pharmaceutical Corp
🇺🇸Raritan, New Jersey, United States
AIDS Research Consortium of Atlanta🇺🇸Atlanta, Georgia, United States